|
|
||||||||
From the NMR Research Unit (Drs. Sastre-Garriga, Ingle, Stevenson, Leary, Miller, and Thompson and D.R. Altmann and M. Cercignani), Institute of Neurology, UCL, London, UK; Neuroimaging Research Unit (Drs. Rovaris and Filippi and B. Benedetti), Department of Neurology, Scientific Institute and University, Ospedale San Raffaele, Milan, Italy; Unitat de Neuroimmunologia Clínica and Unitat de Ressonància Magnètica (Drs. Téllez, Montalban, and Rovira), Institut de Diagnòstic per la Imatge, Hospital General Universitari Vall d'Hebron, Barcelona, Spain; Department of Diagnostic Radiology (Drs. Jasperse, Barkhof, and Kalkers) and Department of Clinical Neurology (Dr. Polman), Free University Hospital, Amsterdam, The Netherlands; Medical Statistics Unit (Dr. Altmann), London School of Hygiene and Tropical Medicine, London, UK; EA 2966 (Drs. Brochet and Dousset), Université Victor Segalen, Bordeaux, France.
Address correspondence and reprint requests to Professor Alan Thompson, Institute of Neurology, UCL, Queen Square, London WC1N 3BG, UK; e-mail: a.thompson{at}ion.ucl.ac.uk.
The authors sought to identify clinical and MRI predictors of outcome in primary progressive multiple sclerosis (PPMS). Clinical and MRI assessments were performed at baseline and 2 and 5 years (clinical only). At baseline, disease duration, expanded disability status scale (EDSS) and brain volume predicted outcome. Adding short-term change variables, baseline EDSS, changes in T2* lesion load and cord area, and number of new lesions were predictive. Clinical and MRI variables predict long-term outcome in PPMS.
Supported by the Spanish Ministry of Health (J.S.G., BEFI #02/9115) and the Wellcome Trust (G.T.I.). The IoN NMR Research Unit is funded by the MS Society of Great Britain and Northern Ireland. This project is an initiative of the E.U. funded MAGNIMS consortium.
Disclosure: The authors report no conflicts of interest.
Received December 3, 2004. Accepted in final form May 5, 2005.
This article has been cited by other articles:
![]() |
J Furby, T Hayton, V Anderson, D Altmann, R Brenner, J Chataway, R. Hughes, K. Smith, D. Miller, and R Kapoor Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1068 - 1075. [Abstract] [PDF] |
||||
![]() |
O. Ciccarelli, C.A. Wheeler-Kingshott, M.A. McLean, M. Cercignani, K. Wimpey, D.H. Miller, and A.J. Thompson Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis Brain, August 1, 2007; 130(8): 2220 - 2231. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Agosta, M. Absinta, M. P. Sormani, A. Ghezzi, A. Bertolotto, E. Montanari, G. Comi, and M. Filippi In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study Brain, August 1, 2007; 130(8): 2211 - 2219. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rovaris, E. Judica, A. Gallo, B. Benedetti, M. P. Sormani, D. Caputo, A. Ghezzi, E. Montanari, A. Bertolotto, G. Mancardi, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years Brain, October 1, 2006; 129(10): 2628 - 2634. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |